Background illustration for clinical trials search

Pancreatic Cancer Clinical Trials

Browse 1,722 pancreatic cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

for
Solid Tumors With HRAS Alterations,
Location: Boston MA, New Brunswick NJ, Pittsburgh PA,
Sponsor: Kura Oncology, Inc.

Sex: All

Age: 18+

Code: NCT06026410

Phase 1, Recruiting

A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors

for
Advanced Solid Tumors, Non-Small Cell Lung Cancer,
Location: Huntersville NC, Grand Rapids MI, Irving TX
Sponsor: AbbVie

Sex: All

Age: 18+

Code: NCT07807956

Phase 1, Recruiting

A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

for
Advanced Solid Tumor, Non-Small Cell Lung Cancer,
Location: Fairfax VA, Tampa FL, Sarasota FL
Sponsor: Blueprint Medicines Corporation

Sex: All

Age: 18+

Code: NCT07629960

Phase 1, Phase 2, Recruiting

A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

for
KRAS-mutant Non-small Cell Lung Cancer (NSCLC),
Location: Boston MA, Philadelphia PA, Fairfax VA, Tampa FL,
Sponsor: Kestrel Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT07458347

Phase 1, Recruiting

Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

for
GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor,
Location: Montreal, Charlottesville VA, Toronto, Jacksonville FL,
Sponsor: RayzeBio, Inc.

Sex: All

Age: 18+

Code: NCT07165132

Phase 1, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

for
Advanced Solid Malignancies, Non-small Cell Lung Cancer (NSCLC),
Location: Baltimore MD, Fairfax VA, Toronto, San Antonio TX,
Sponsor: Bristol-Myers Squibb

Sex: All

Age: 18+

Code: NCT07223047

Phase 1, Phase 2, Recruiting

SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors

for
Selected Advanced Solid Tumors, Colorectal Cancer (CRC),
Location: Glen Burnie MD
Sponsor: SK Life Science, Inc.

Sex: All

Age: 18+

Code: NCT07812805

Phase 1, Recruiting

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

for
Ovarian Neoplasms, Breast Neoplasms,
Location: Boston MA, New York NY, Philadelphia PA, Glen Burnie MD,
Sponsor: Eli Lilly and Company

Sex: All

Age: 18+

Code: NCT07213791

Phase 1, Recruiting

Using Tumor Models to Determine Treatments

for
Pancreatic Ductal Carcinoma, Advanced Cancer, Epithelial Tumor
Location: Toronto
Sponsor: University Health Network, Toronto

Sex: All

Age: 18+

Code: NCT06813079

Phase 2, Recruiting

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

for
Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer,
Location: Boston MA, New York NY, Philadelphia PA, Baltimore MD,
Sponsor: Verastem, Inc.

Sex: All

Age: 18+

Code: NCT07020221

Phase 1, Phase 2, Recruiting

Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers

for
Stage IV Esophageal Adenocarcinoma,
Location: San Francisco CA
Sponsor: University of California, San Francisco

Sex: All

Age: 18+

Code: NCT04221893

Recruiting

A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors

for
Solid Tumor, Adult, Colorectal Cancer,
Location: Houston TX
Sponsor: Crossignal Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT06598007

Phase 1, Phase 2, Recruiting

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

for
Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC),
Location: Boston MA, New York NY, Baltimore MD, Fairfax VA,
Sponsor: Revolution Medicines, Inc.

Sex: All

Age: 18+

Code: NCT05379985

Phase 1, Phase 2, Recruiting

Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors

for
Bladder Cancer, Head and Neck Squamous Cell Carcinoma,
Location: Houston TX
Sponsor: Baylor College of Medicine

Sex: All

Age: 18+

Code: NCT03740256

Phase 1, Recruiting

ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours

for
Advanced Solid Tumor, PDAC, HNSCC
Location: Boston MA, New Haven CT, New York NY, St Louis MO,
Sponsor: Adcendo ApS

Sex: All

Age: 18+

Code: NCT06597721

Phase 1, Recruiting
New

Three Times Weekly Symptom Screening for Children With Cancer

for
Cancer, Relapsed Cancer
Location: Toronto
Sponsor: The Hospital for Sick Children

Sex: All

Age: 2 - 18

Code: NCT04275102

Recruiting
New

Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors

for
Advanced Solid Tumors
Location: Huntersville NC
Sponsor: Regeneron Pharmaceuticals

Sex: All

Age: 18+

Code: NCT07863024

Phase 1, Phase 2, Recruiting
New

A Multicenter, Open-label, Phase 1/1b, Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SI-B037 in Solid Tumors

for
Locally Advanced /Metastatic Solid Tumors,
Location: Houston TX
Sponsor: SystImmune Inc.

Sex: All

Age: 18+

Code: NCT07940881

Phase 1, Recruiting
New

Medically Tailored Meals to Improve Cancer Outcomes

for
Cancer, Healthy Eating
Location: St Louis MO
Sponsor: Washington University School of Medicine

Sex: All

Age: 18+

Code: NCT07924241

Recruiting
New

Improving Care Delivery for Patients With Mental Illness and Cancer Across a Cancer Center Network

for
Cancer, Serious Mental Illness
Location: Boston MA
Sponsor: Massachusetts General Hospital

Sex: All

Age: 18+

Code: NCT07707362

Recruiting

What is pancreatic cancer?

The pancreas sits deep behind the stomach and makes both digestive enzymes and hormones like insulin. About 92 percent of pancreatic cancers start in the enzyme making cells, and this page is mostly about those. The other 8 percent are neuroendocrine tumors, which grow more slowly, have their own trials, and a five year survival of 72 percent against 8 percent. The pancreas gives no early warning. Jaundice, back pain, weight loss and new diabetes usually appear only after the cancer has grown or spread, and fewer than 20 percent of people can have surgery at diagnosis.

Smoking roughly doubles the risk, and type 2 diabetes, extra weight, chronic pancreatitis and family history raise it. About 10 percent of cases come from inherited mutations, so guidelines now recommend genetic testing for everyone diagnosed. That can change treatment and flag relatives who should be watched. The hope comes from biology. More than 90 percent of pancreatic cancers carry a KRAS mutation. That target was called undruggable for decades. Now several RAS inhibitors are in trials, with the first Phase 3 studies recruiting. Pancreatic cancer shares risk factors with type 2 diabetes and inherited genes with breast and ovarian cancer.

Article preview image

Our guide to new treatments for pancreatic cancer covers what has been approved and what is being tested.

Research Paving The Way To A New Treatment For Pancreatic Cancer

Types of pancreatic cancer clinical trials

Who can participate in pancreatic cancer clinical trials?

What causes pancreatic cancer?

The stages of pancreatic cancer, and why they matter for trials

How to enroll in a pancreatic cancer clinical trial